INTRODUCTION: Measurement of @entity5 response by standard response criteria is challenging in @entity8646 , especially when the pleura is involved, as it often is in stage IV disease. In this study, we aimed to determine the effectiveness of volumetric response evaluation criteria in @entity5 (volumetrics) for evaluating response in @entity1 with @entity8646 treated on a phase II study of @entity32431 . METHODS: We evaluated the @entity5 responses of 25 @entity1 with @entity6732 using computed tomography-based RECIST, World Health Organization (WHO), modified RECIST, and volumetrics. As a control, we assessed 37 @entity1 with @entity1149 ( @entity1149 ) with RECIST and volumetrics. RESULTS: Agreement analyses in 23 @entity1 with @entity6732 at the time of RECIST-determined @entity74 ( @entity74 ) compared volumetrics with RECIST, modified RECIST, and WHO criteria. Use of volumetrics was associated with 22% discordance compared with RECIST, 15% versus modified RECIST, and 22% versus WHO criteria. Volumetrics revealed @entity74 72 days earlier than RECIST (p = 0.016). In another cohort of 35 @entity1 with @entity1149 , there was 9% discordance between volumetrics and RECIST at the time of @entity74 . Volumetrics demonstrated @entity74 32 days earlier than RECIST in @entity1149 (p = 0.0078). CONCLUSIONS: Our study suggests that volumetrics might improve detection of @entity74 . Prospective evaluation of this technique in a larger series of @entity1 with @entity8646 will be required.

Assessment of objective responses using volumetric evaluation in advanced XXXX and metastatic @entity1149 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity8646 :: ('MESH:C564767', 'Disease') :: ['thymic malignancies'] @entity32431 :: ('MESH:C487081', 'Chemical') :: ['belinostat'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'solid tumors'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small cell lung cancer'] @entity6732 :: ('MESH:D013953', 'Disease') :: ['thymic cancer'] @entity74 :: ('MESH:D030342', 'Disease') :: ['PD', 'progressive disease']
@entity8646 :: (MESH:C564767,Disease) :: ['thymic malignancies']
